Exploration of new diagnostic biomarkers in patients with eosinophilic granulomatous polyangiitis

Validation of different diagnostic criteria and exploration of new diagnostic biomarkers in patients with eosinophilic granulomatous polyangiitis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300067542

Enrollment

Unknown

Registered

2023-01-11

Start date

2023-01-11

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eosinophilic granulomatous polyangiitis

Interventions

EGPA:Not involved

Asthma:Not involved

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Meeting the 2022ACR/EULAR classification criteria for eosinophilic granulomatous polyangiitis (2) Untreated or relapsed patients

Exclusion criteria

Exclusion criteria: (1) Combined with infectious disease. (2) Combined with malignancy. (3) Qualified induced sputum samples cannot be obtained. (4) Prednisone (or equivalent dose of other glucocorticoids)>15mg/d was taken before enrollment.

Design outcomes

Primary

Measure	Time frame
sputum concentration of IL-5;	—

Secondary

Measure	Time frame
sputum concentration of IL-4;sputum concentration of IL-13;sputum concentration of IL-17;sputum concentration of IL-6;sputum ANCA;serum concentration of IL-5;serum concentration of IL-4;serum concentration of IL-13;serum concentration of IL-17;serum concentration of IL-6;	—

Countries

China

Contacts

Public ContactTing Zhang

Peking Union Medical College Hospital

tintin-03@163.com+8613811583221

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026